References
- Acunzo M, Romano G, Palmieri D, et al (2013). Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2. Proc Natl Acad Sci U S A, 110, 8573-8. https://doi.org/10.1073/pnas.1302107110
- Al Dayel F (2012). EGFR mutation testing in non-small cell lung cancer (NSCLC). J Infect Public Health, 5, S31-4. https://doi.org/10.1016/j.jiph.2012.09.008
- Al Zobair AA, Al Obeidy BF, Yang L, et al (2013). Concomitant overexpression of EGFR and CXCR4 is associated with worse prognosis in a new molecular subtype of non-small cell lung cancer. Oncol Rep, 29, 1524-32.
- Araki T, Yashima H, Shimizu K, et al (2012). Review of the treatment of non-small cell lung cancer with gefitinib. Clin Med Insights Oncol, 6, 407-21.
- Aydiner A, Yildiz I, Seyidova A (2013). Clinical Outcomes and Prognostic Factors Associated with the Response to Erlotinib in Non-Small-Cell Lung Cancer Patients with Unknown EGFR Mutational Status. Asian Pac J Cancer Prev, 14, 3255-61. https://doi.org/10.7314/APJCP.2013.14.5.3255
- Chen G, Kronenberger P, Teugels E, et al (2013). Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents. Biochem Biophys Res Commun, 431, 623-9. https://doi.org/10.1016/j.bbrc.2012.12.070
- Han Y, Wang XB, Xiao N, et al (2013). mRNA Expression and Clinical Significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in Postoperative Patients with Non-Small Cell Lung Cancer. Asian Pac J Cancer Prev, 14, 987-90. https://doi.org/10.7314/APJCP.2013.14.5.2987
- Jeon WI, Ryu PD, Lee SY (2012). Effects of voltage-gated K+ channel blockers in gefitinib-resistant H460 non-small cell lung cancer cells. Anticancer Res, 32, 5279-84.
- Karachaliou N, Costa C, Gimenez-Capitan A, et al (2013). BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations. J Thorac Oncol, 8, 295-300. https://doi.org/10.1097/JTO.0b013e31827db621
- Lee E, Keam B, Kim DW, et al (2013). Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. J Thorac Oncol, 8, 1069-74. https://doi.org/10.1097/JTO.0b013e318294c8e8
- Lee KH, Lee KY, Jeon YJ, et al (2012). Gefitinib in Selected Patients with Pre-Treated Non-Small-Cell Lung Cancer: Results from a Phase IV, Multicenter, Non-Randomized Study (SELINE). Tuberc Respir Dis (Seoul), 73, 303-11. https://doi.org/10.4046/trd.2012.73.6.303
-
Liang J, Qian Y, Xu D, et al (2013). Serum Tumor Markers, Hypoxia-Inducible factor-
$1{\alpha}$ HIF-$1{\alpha}$ and Vascular Endothelial Growth Factor, in Patients with Non- small Cell Lung Cancer Before and after Intervention. Asian Pac J Cancer Prev, 14, 3851-4. https://doi.org/10.7314/APJCP.2013.14.6.3851 - Liu YC, Zhou SB, Gao F, et al (2013). Chemotherapy and late course three dimensional conformal radiotherapy for treatment of patients with stage III non- small cell lung cancer. Asian Pac J Cancer Prev, 14, 2663-5. https://doi.org/10.7314/APJCP.2013.14.4.2663
- Lopez-Rios F, Angulo B, Gomez B, Mair D, et al (2013). Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. J Clin Pathol, 66, 381-5. https://doi.org/10.1136/jclinpath-2012-201240
- Louis RA, Rajendranath R, Ganesan P, et al (2012). First report of upfront treatment with Gefitinib in comparison with chemotherapy in advanced non-small cell lung cancer patients from south India: Analysis of 120 patients. Indian J Med Paediatr Oncol, 33, 146-54. https://doi.org/10.4103/0971-5851.103141
- Lu YY, Huang XE, Xu L, et al (2013). Potential predictors of sensitivity to pemetrexed as first-line chemotherapy for patients with advanced non-squamous NSCLCs. Asian Pac J Cancer Prev, 14, 2005-8. https://doi.org/10.7314/APJCP.2013.14.3.2005
- Maftouh M, Avan A, Galvani E, et al (2013). Molecular mechanisms underlying the role of microRNAs in resistance to epidermal growth factor receptor-targeted agents and novel therapeutic strategies for treatment of non-small-cell lung cancer. Crit Rev Oncog, 18, 317-26. https://doi.org/10.1615/CritRevOncog.2013007191
- Morabito A, Costanzo R, Rachiglio AM, et al (2013). Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations. J Thorac Oncol, 8, e59-60. https://doi.org/10.1097/JTO.0b013e318286cc26
- Sakai A, Kasahara K, Sone T (2013). Detection of EGFR T790M mutation in pericardial effusion from a non-small cell lung cancer patient with erlotinib therapy. Case Rep Oncol, 6, 15-20. https://doi.org/10.1159/000345947
- Sechler M, Cizmic AD, Avasarala S, et al (2013). Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategies. Pharmgenomics Pers Med, 6, 25-36.
- Shrestha S, Joshi P (2012). Gefitinib monotherapy in advanced non-small-cell lung cancer: a retrospective analysis. J Nepal Med Assoc, 52, 66-71.
- Sudo M, Chin TM, Mori S, et al (2013). Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer. Cancer Chemother Pharmacol, 71, 1325-34. https://doi.org/10.1007/s00280-013-2132-y
- Tanaka K, Hata A, Kaji R, et al (2013). Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation. J Thorac Oncol, 8, 892-8. https://doi.org/10.1097/JTO.0b013e31828c3929
- Tomonaga N, Nakamura Y, Yamaguchi H, et al (2013). Analysis of intratumor heterogeneity of EGFR mutations in mixed type lung adenocarcinoma. Clin Lung Cancer.
- Wheler J, Falchook G, Tsimberidou AM, et al (2013). Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD anderson cancer center phase I population. Oncotarget, 4, 772-84.
- Wu C, Li F, Jiao SC (2012). Prognostic factors for survival of patients with extensive stage small cell lung cancer--a retrospective single institution analysis. Asian Pac J Cancer Prev, 13, 4959-62. https://doi.org/10.7314/APJCP.2012.13.10.4959
Cited by
- Clinical Study on Mannan Peptide Combined with TP Regimen in Treating Patients with Non-small Cell Lung Cancer vol.14, pp.8, 2013, https://doi.org/10.7314/APJCP.2013.14.8.4801
- Preliminary Evaluation of Clinical Utility of CYFRA 21-1, CA 72-4, NSE, CA19-9 and CEA in Stomach Cancer vol.15, pp.12, 2014, https://doi.org/10.7314/APJCP.2014.15.12.4933
- Serum Carcinoembryonic Antigen Levels before Initial Treatment are Associated with EGFR Mutations and EML4-ALK Fusion Gene in Lung Adenocarcinoma Patients vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.3927
- Correlation between Serum Carcinoembryonic Antigen Level and Histologic Subtype in Resected Lung Adenocarcinoma vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3857
- Label-free Electrochemical Aptasensor for Carcino-embryonic Antigen Based on Ternary Nanocomposite of Gold Nanoparticles, Hemin and Graphene vol.28, pp.5, 2015, https://doi.org/10.1002/elan.201500593